Drug intelligence / Profile preview

Novel TCR-T

Development stage: Preclinical
Lead developer: Axis Therapeutics
Modality: TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

Novel TCR-T is a preclinical-stage T-cell receptor (TCR) engineered T-cell therapy being developed by PharmaEssentia. This cell therapy involves the genetic modification of a patient's T cells to express a specific TCR designed to recognize a novel, undisclosed tumor-associated antigen. Once these engineered T cells are re-infused into the patient, they are intended to identify and eliminate cancer cells expressing the target antigen through the natural cytotoxic mechanisms of the immune system. The program represents part of PharmaEssentia's research into next-generation immunotherapies for the treatment of malignancies.

Other names: Novel TCR-TPharmaEssentia Novel TCR-T

Beyond the preview

Go deeper on Novel TCR-T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novel TCR-T.

Explore the full profile